Article
Does the clopidogrel CYP2C19 genotype assay predict postprocedure stenosis in cerebral aneurysms treated with a flow diverter?
Neurosurgical focus - 1 Oct 2023
Allen Austin J, Gelinne Aaron, Quig Nathan S, Reed Samuel, Shastri Darshan, Ho James P, Yap Edward
Abstract excerpt
OBJECTIVE: Flow diverters have emerged as a popular modality for treating cerebral aneurysms but require dual antiplatelet therapy (DAPT) after placement. Clopidogrel is a common choice but is a prodrug that some patients may not convert into an active metabolite. The CYP2C19 genotype assay is used to predict activation speed; however, limited data exist showcasing whether this genotype accurately predicts...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
